

Juraj Adamik

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4121372/publications.pdf>

Version: 2024-02-01

23
papers

359
citations

759233

12
h-index

839539

18
g-index

23
all docs

23
docs citations

23
times ranked

634
citing authors

#	ARTICLE	IF	CITATIONS
1	EZH2 or HDAC1 Inhibition Reverses Multiple Myeloma-Induced Epigenetic Suppression of Osteoblast Differentiation. <i>Molecular Cancer Research</i> , 2017, 15, 405-417.	3.4	57
2	The Role of Semaphorin 4D in Bone Remodeling and Cancer Metastasis. <i>Frontiers in Endocrinology</i> , 2018, 9, 322.	3.5	39
3	Distinct Mechanisms for Induction and Tolerance Regulate the Immediate Early Genes Encoding Interleukin 1 β and Tumor Necrosis Factor α . <i>PLoS ONE</i> , 2013, 8, e70622.	2.5	33
4	Osteoblast suppression in multiple myeloma bone disease. <i>Journal of Bone Oncology</i> , 2018, 13, 62-70.	2.4	28
5	EZH2 Supports Osteoclast Differentiation and Bone Resorption Via Epigenetic and Cytoplasmic Targets. <i>Journal of Bone and Mineral Research</i> , 2020, 35, 181-195.	2.8	26
6	Distinct mechanisms regulate IL1B gene transcription in lymphoid CD4 T cells and monocytes. <i>Cytokine</i> , 2018, 111, 373-381.	3.2	25
7	The IL17A and IL17F loci have divergent histone modifications and are differentially regulated by prostaglandin E2 in Th17 cells. <i>Cytokine</i> , 2013, 64, 404-412.	3.2	23
8	XRK3F2 Inhibition of p62-ZZ Domain Signaling Rescues Myeloma-Induced GFI1-Driven Epigenetic Repression of the Runx2 Gene in Pre-osteoblasts to Overcome Differentiation Suppression. <i>Frontiers in Endocrinology</i> , 2018, 9, 344.	3.5	20
9	Impact of checkpoint blockade on cancer vaccine-activated CD8+ T cell responses. <i>Journal of Experimental Medicine</i> , 2020, 217, .	8.5	20
10	Epigenetic-Based Mechanisms of Osteoblast Suppression in Multiple Myeloma Bone Disease. <i>JBMR Plus</i> , 2019, 3, e10183.	2.7	19
11	Cell trafficking and regulation of osteoblastogenesis by extracellular vesicle associated bone morphogenetic protein 2. <i>Journal of Extracellular Vesicles</i> , 2021, 10, e12155.	12.2	16
12	Dysregulated NF- κ B-Dependent ICOSL Expression in Human Dendritic Cell Vaccines Impairs T-cell Responses in Patients with Melanoma. <i>Cancer Immunology Research</i> , 2020, 8, 1554-1567.	3.4	15
13	Immunomodulatory impact of α -fetoprotein. <i>Trends in Immunology</i> , 2022, 43, 438-448.	6.8	13
14	A Novel Sulforaphane-Regulated Gene Network in Suppression of Breast Cancer-Induced Osteolytic Bone Resorption. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 420-431.	4.1	10
15	A combined computational and experimental approach reveals the structure of a C/EBP β -Spi1 interaction required for IL1B gene transcription. <i>Journal of Biological Chemistry</i> , 2018, 293, 19942-19956.	3.4	5
16	EZH2 Inhibitor GSK126 Exhibits Osteo-Anabolic Properties in MM Bone Disease and Synergizes with Bortezomib to Inhibit MM Cell Viability. <i>Blood</i> , 2016, 128, 3247-3247.	1.4	3
17	Increase of Gfi1 Acetylation by HDAC Inhibitors Blocks Gfi1-Mediated Runx2 Repression in Osteoblast Precursors in Multiple Myeloma Bone Disease. <i>Blood</i> , 2013, 122, 753-753.	1.4	2
18	Semaphorin 4D to suppress bone formation in multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 8039-8039.	1.6	2

#	ARTICLE	IF	CITATIONS
19	Epigenetics of Multiple Myeloma Bone Disease. <i>Current Molecular Biology Reports</i> , 2019, 5, 86-96.	1.6	1
20	TBK1/Ikk μ Inhibitor Amlx Blocks Multiple Myeloma Cell Growth in Vitro and In Vivo. <i>Blood</i> , 2018, 132, 4504-4504.	1.4	1
21	Novel dendritic cell vaccine strategies. , 2022, , 109-135.		1
22	The Pâ€TEFbâ€dependent Gene Coding for ILâ€1 β is More Sensitive to Cellular Metabolism than that of the BRD4â€dependent TNF α â€coding Gene. <i>FASEB Journal</i> , 2013, 27, 769.8.	0.5	0
23	LIM-Domain Protein Ajuba Is a Required Co-Factor for Gfi1-Induced Epigenetic Switch Regulating Runx2 Repression in Multiple Myeloma-Exposed Pre-Osteoblasts. <i>Blood</i> , 2015, 126, 4216-4216.	1.4	0